Table 2.

Ongoing HIV Vaccine Efficacy Trials, as of July 2023

Study	Phase	Population	Regimen	Trials sites	Design	ClinicalTrials.gov identifier
HPX2008/HVTN705 IMBOKODOa	2b	2,600 women aged 18–35 years	Active immunization using Ad26.Mos4.HIV + Clade C gp140 vaccine for prime boost. Clade C gp140 only for boosters. Four injections over a 12-month period.	26 sites in 5 countries Africa	Placebo-controlled, randomized, double blind.	NCT03060629
HPX3002/HVTN706 MOSAICOa	3	3,800 HIV-negative men and transgender people who have sex with men, aged 18–60 years	Active immunization using Ad26.Mos4.HIV + Clade C and Mosaic gp140 vaccine, for prime and booster doses. Four injections over a 12-month period.	EU, Africa, South America	Placebo-controlled, randomized, double-blind—preferentially recruiting volunteers who do not want to take PrEP	NCT03964415
PrEPVAcc	2b	Up to 1,668 adults (18–40 years)	Two experimental vaccine regimens: DNA-HIV-PT123 + monomeric AIDSVAX B/E and DNA-HIV-PT123 + CN54gp140 + MVA CMDR (weeks 0, 4, 24, 48) and DNA/CN54gp140 (weeks 0, 4)+MVA/CN54gp140. Four injections over 48 weeks.	Four African countries	Three-arm, two-stage HIV prophylactic vaccine trial, with concurrent open-label randomization to daily TAF/FTC or TDF/FTC PrEP (weeks 0–26). Placebo-controlled, randomized, double-blind.	NCT04066881

^a Vaccinations stopped due to futility.

TAF, Tenofovir alafenamide; TDF/FTC, Tenofovir disoproxil fumarate/emtricitabine.